News & Updates

New drug applications approved by US FDA as of 16 - 31 December 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In acute myeloid leukaemia (AML) patients who received the 7+3* induction, a higher daunorubicin dose or a double induction did not seem to yield better outcomes, findings from the two-part phase III SAL Dauno-Double trial suggest.

Stopping treatment with renin–angiotensin system (RAS) inhibitors in patients with advanced chronic kidney disease does not appear to raise the levels of estimated glomerular filtration rate (eGFR) or decelerate its decline, according to a study.

Individuals with cold agglutinin disease (CAD), a rare, chronic, autoimmune haemolytic anaemia, had sustained improvements in patient-reported outcomes (PROs) and quality of life (QoL) following treatment with the C1s complement inhibitor sutimlimab, findings from part B of the phase III CADENZA trial have shown.